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Checkpoints: How to activate p53
Thomas Caspari
The tumour suppressor protein p53 is stabilised and
activated in response to ionising radiation. This is
known to depend on the kinase ATM; recent results
suggest ATM acts via the downstream kinase
Chk2/hCds1, which stabilises p53 at least in part by
direct phosphorylation of residue serine 20.
Address: MRC Cell Mutation Unit, University of Sussex, Brighton
BN1 9RR, UK.
E-mail: T.Caspari@sussex.ac.uk
Current Biology 2000, 10:R315–R317
0960-9822/00/$ – see front matter 
© 2000 Elsevier Science Ltd. All rights reserved.
One in three people are touched by cancer at least once
in their lifetime. Over half of human tumours are associ-
ated with mutations that either directly affect the protein
p53 or affect components of pathways that regulate p53.
The discovery that ‘checkpoint’ pathways, which
monitor the structural integrity of our chromosomes, sta-
bilise and activate p53 in response to DNA damage indi-
cated how these control systems act to protect organisms
from the potentially harmful effects of damaged cells [1].
Upon activation, p53 induces the expression of a variety
of gene products, which cause either a prolonged cell-
cycle arrest in G1, thereby preventing proliferation of
damaged cells, or apoptosis, thereby removing damaged
cells from our body. 
Checkpoint activation requires recognition of DNA
damage. Two serine/threonine kinases, ATM and ATR,
are thought to act at an early stage in damage sensing. A-T
cells, which are derived from cancer-prone ataxia-
telangiectasia patients, lack a functional ATM kinase and
exhibit chromosomal instability and radiosensitivity.
These cells show a significant delay in the up-regulation
of p53 in response to ionising radiation, and this defect
correlates with a delay in phosphorylation of a serine
residue (serine 15) within the amino-terminal transactiva-
tion domain of p53 [2] (Figure 1). While A-T cells are
aberrant in their response to ionising radiation, they show
normal UV sensitivity and p53 activation in response to
UV-induced DNA damage. The observation that over-
expression of a kinase-inactive form of ATR interferes
with phosphorylation of p53 residue serine 15 in response
to UV light [3] argues that both ATM and ATR up-
regulate p53 by targeting serine 15.
These observations suggested an attractive model in
which phosphorylation of p53 at serine 15 prevented its
interaction with MDM2, the protein which targets p53
for proteolysis and prevents its accumulation in undam-
aged cells. But a link between p53 stabilisation and
serine 15 phosphorylation is not consistent with several
reports published last year [4–6]. The biochemical evi-
dence suggests that the mechanism by which serine 15
contributes to p53 activation involves increased binding
of phosphorylated p53 to the transcriptional activator
CBP/p300, rather than a disassociation of the
p53–MDM2 complex [4]. 
Serine 20 of p53 lies directly within the MDM2–p53
interaction domain, and the observation that replacement
of this residue by alanine abrogates p53 stabilisation in
response to both ionising radiation and UV light [5] shifted
the focus of research from serine 15 to serine 20. In vitro
experiments using peptides bearing non-phosphorylated
serine 20 or an alanine substitution provided further
support for the importance of this serine residue in the
p53-MDM2 interaction [6]. These peptides compete with
p53 for MDM2 binding, whereas a similar peptide contain-
ing a phosphorylated serine 20 allows the p53–MDM2
association. While ATM is clearly required to activate p53
in response to ionising radiation, both ATM and ATR fail
to phosphorylate p53 residue serine 20 in vitro, indicating
that, most likely, this residue is targeted by other kinases
which act downstream of ATM and ATR.
Two ideal candidates for this job are Chk1 and Chk2,
two serine/threonine kinases which become phosphory-
lated in response to various forms of DNA damage. Chk2
is of particular interest, because it is phosphorylated in
an ATM-dependent manner upon treatment with ionis-
ing radiation [7]. A new study using Chk2-deficient thy-
mocytes [8] has now shown that Chk2 is indeed required
for p53 to be stabilised in response to ionising radiation,
and that it is able to phosphorylate p53 at serine 20
in vitro. These new results support a model in which
ATM activates Chk2 in response to DNA damage
caused by ionising radiation, and that activated Chk2
triggers stabilisation of p53 by phosphorylating residue
serine 20 (Figure 2). 
This model is further supported by the recent results of
Chehab et al. [9]. This group has demonstrated that
Chk2 is able to phosphorylate p53 on serine 20, and that
this phosphorylation event triggers dissociation of pre-
formed complexes between p53 and MDM2 under
in vitro conditions. Furthermore, ectopic expression of
wild-type Chk2 was found to stabilise p53 after DNA
damage, whereas expression of a dominant-negative
mutant form of Chk2 abrogated both phosphorylation of
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serine 20 and p53 stabilisation [9]. A close link between
Chk2 and p53 is consistent with the recent finding that
the Chk2 gene can be mutated in patients suffering from
the multicancer disease known as Li-Fraumeni syn-
drome [10]. This syndrome results normally from the
inheritance of a mutant p53 gene, but analysis of an
affected family that carries a wild-type p53 gene revealed
a germ-line mutation in Chk2.
While Chk2 is required to activate p53 in response to
ionising radiation, Hirao et al. [8] found that Chk2 is
dispensable for the p53 response in the presence of UV-
induced damage. Although there is little definitive experi-
mental evidence, both this observation and the fact that
UV damage triggers a normal p53 response in A-T cells
support a model in which ATR and Chk1, rather than
ATM and Chk2, activate p53 in response to UV-induced
damage (Figure 2). Consistent with such a model, Shieh
et al. [11] have found that Chk1 is able to phosphorylate
p53 at serine 20 in vitro, and that overexpression of a
kinase-defective mutant form of Chk1 leads to reduced
levels of p53 protein in co-transfected cells.
There is, however, still much uncertainty about the
physiological roles of individual phosphorylation sites in
p53. A recent report [12] indicates that it is possible to
strip p53 of all of its phosphorylation sites, including
serine 15 and serine 20, without significantly affecting
either the stabilisation or function of the protein. This
result suggests that ATM may promote p53 stabilisation
by mediating simultaneous phosphorylation of both part-
ners of the p53–MDM2 complex. Consistent with this
suggestion, ATM-dependent phosphorylation of MDM2
has been reported to occur in response to ionising radia-
tion [13]. The complexity of the amino-terminal phospho-
rylation events may reflect a role in modulating the
transcriptional activity of p53, depending on the cellular
environment or the type of DNA damage. In this context
it will be very interesting to address the physiological role
of individual p53 modifications by constructing mice
expressing defined mutant forms of p53.
The finding that multiple ATM-dependent phosphoryla-
tion events occur within the amino-terminal transactiva-
tion domain of p53 raise another question. Why does
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Figure 1
Four possible ways of activating the tetrameric transcription factor p53 in
response to DNA damage. DNA damage is recognised by checkpoint
proteins, which target p53 in order to arrest cell-cycle progression in G1
or to promote apoptosis. Dephosphorylation of serine 376 appears to
promote binding of a 14-3-3 dimer to p53, which correlates with an
increase in its DNA binding affinity. The numbers refer to serine residues
phosphorylated in vivo. Domains of p53: TA, transactivation domain; DNA,
DNA-binding domain; 4, tetramerisation domain; R, regulatory domain. 
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ATM target p53 at residue serine 15, while Chk2, which
acts downstream of ATM, phosphorylates residue serine
20 in response to ionising radiation? It is not clear,
however, whether the same p53 molecule is subjected to
both modifications, or whether these modifications reflect
events in different cell types. In fact, p53 shows even
more ATM-dependent responses to DNA damage. ATM
is not only required to stabilise p53 but also to increase its
affinity for specific promoter sequences. 
The DNA-binding affinity of p53 appears to be regulated
by modifications within the carboxy-terminal regulatory
domain (Figure 1). This region contains one serine
residue, serine 376, which is dephosphorylated in
response to DNA damage [14], and several lysine
residues, which are acetylated upon DNA damage [15].
Dephosphorylation of serine 376 is ATM-dependent and
stimulates the DNA-binding activity of p53 [14]. Acetyla-
tion of p53 is up-regulated by phosphorylation of the
amino-terminal transactivation domain in vitro, and recent
evidence suggests that ATM may stimulate p53 acetyla-
tion by phosphorylating residue serine 15 and thereby
recruiting the acetyl-transferase CBP/p300 to 53 [4].
Hirao et al. [8] have reported that Chk2 has a second func-
tion, in addition to its crucial role in promoting p53 stabili-
sation. They found that Chk2 is required to maintain
cell-cycle arrest in G2 in a p53-independent manner upon
ionising radiation. This aspect of the DNA damage check-
point resembles very much the checkpoint organisation in
unicellular organisms. While p53 is not found in unicellu-
lar yeast cells, the organisation of the checkpoint pathways
is highly conserved [16]. Upon detection of DNA damage,
an ATM-related protein kinase, Rad3Sp/Mec1Sc, activates
the Chk2-homologue Cds1Sp/Rad53Sc in order to arrest
the cell cycle (Figure 2). During evolution, p53 might
have become part of these pre-existing pathways in order
to allow the removal of damaged cells. 
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Figure 2
Model for the checkpoint-dependent activation of p53. See text for
details. IR, ionising radiation; Sp, Schizosaccharomyces pombe;
Sc, Saccharomyces cerevisiae.
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